Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7VMZ

Crystal structure of a human Coronavirus 229E antibody C04 Fab

Summary for 7VMZ
Entry DOI10.2210/pdb7vmz/pdb
DescriptorC04 Fab Light Chain, C04 Fab Heavy Chain (2 entities in total)
Functional Keywordsthe antibody c04 targeted rbd of human coronavirus 229e spike, immune system
Biological sourceHomo sapiens (human)
More
Total number of polymer chains2
Total formula weight47648.00
Authors
Xiang, J.C.,Yang, B. (deposition date: 2021-10-10, release date: 2022-10-12, Last modification date: 2024-11-13)
Primary citationXiang, J.,Su, J.,Lan, Q.,Zhao, W.,Zhou, Y.,Xu, Y.,Niu, J.,Xia, S.,Qi, Q.,Sidhu, S.,Lu, L.,Miersch, S.,Yang, B.
Antigenic mapping reveals sites of vulnerability on alpha-HCoV spike protein.
Commun Biol, 5:1179-1179, 2022
Cited by
PubMed Abstract: Understanding the antigenic signatures of all human coronaviruses (HCoVs) Spike (S) proteins is imperative for pan-HCoV epitopes identification and broadly effective vaccine development. To depict the currently elusive antigenic signatures of α-HCoVs S proteins, we isolated a panel of antibodies against the HCoV-229E S protein and characterized their epitopes and neutralizing potential. We found that the N-terminal domain of HCoV-229E S protein is antigenically dominant wherein an antigenic supersite is present and appears conserved in HCoV-NL63, which holds potential to serve as a pan-α-HCoVs epitope. In the receptor binding domain, a neutralizing epitope is captured in the end distal to the receptor binding site, reminiscent of the locations of the SARS-CoV-2 RBD cryptic epitopes. We also identified a neutralizing antibody that recognizes the connector domain, thus representing the first S2-directed neutralizing antibody against α-HCoVs. The unraveled HCoVs S proteins antigenic similarities and variances among genera highlight the challenges faced by pan-HCoV vaccine design while supporting the feasibility of broadly effective vaccine development against a subset of HCoVs.
PubMed: 36333470
DOI: 10.1038/s42003-022-04160-8
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.85 Å)
Structure validation

248335

PDB entries from 2026-01-28

PDB statisticsPDBj update infoContact PDBjnumon